By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company AxoGen, Inc.

AxoGen, Inc. (AXGN)

NASDAQ Currency in USD
$16.80
+$0.73
+4.54%
Last Update: 11 Sept 2025, 20:00
$773.01M
Market Cap
-163.27
P/E Ratio (TTM)
Forward Dividend Yield
$9.22 - $21.00
52 Week Range

AXGN Stock Price Chart

Explore AxoGen, Inc. interactive price chart. Choose custom timeframes to analyze AXGN price movements and trends.

AXGN Company Profile

Discover essential business fundamentals and corporate details for AxoGen, Inc. (AXGN) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Medical - Devices

IPO Date

17 Dec 1986

Employees

451.00

CEO

Michael D. Dale

Description

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

AXGN Financial Timeline

Browse a chronological timeline of AxoGen, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 6 May 2026

Upcoming earnings on 23 Feb 2026

Upcoming earnings on 6 Nov 2025

EPS estimate is $0.08.

Earnings released on 5 Aug 2025

EPS came in at $0.12 surpassing the estimated $0.06 by +100.00%, while revenue for the quarter reached $56.66M , missing expectations by -0.40%.

Earnings released on 8 May 2025

EPS came in at -$0.02 falling short of the estimated -$0.01 by -100.00%, while revenue for the quarter reached $48.56M , missing expectations by -8.97%.

Earnings released on 25 Feb 2025

EPS came in at $0.08 surpassing the estimated $0.04 by +100.00%, while revenue for the quarter reached $49.41M , beating expectations by +2.33%.

Earnings released on 7 Nov 2024

EPS came in at $0.07 surpassing the estimated $0.01 by +1.07K%, while revenue for the quarter reached $48.64M , beating expectations by +2.53%.

Earnings released on 8 Aug 2024

EPS came in at $0.05 surpassing the estimated -$0.05 by +200.00%, while revenue for the quarter reached $47.91M , beating expectations by +10.42%.

Earnings released on 2 May 2024

EPS came in at -$0.06 surpassing the estimated -$0.10 by +40.00%, while revenue for the quarter reached $41.38M , missing expectations by -4.64%.

Earnings released on 5 Mar 2024

EPS came in at -$0.06 surpassing the estimated -$0.09 by +33.33%, while revenue for the quarter reached $42.92M , beating expectations by +3.05%.

Earnings released on 7 Nov 2023

EPS came in at $0.01 surpassing the estimated -$0.08 by +112.50%, while revenue for the quarter reached $41.27M , beating expectations by +1.45%.

Earnings released on 7 Aug 2023

EPS came in at -$0.03 surpassing the estimated -$0.15 by +80.00%, while revenue for the quarter reached $38.16M , missing expectations by -2.37%.

Earnings released on 9 May 2023

EPS came in at -$0.10 surpassing the estimated -$0.15 by +33.33%, while revenue for the quarter reached $36.66M , beating expectations by +3.66%.

Earnings released on 14 Mar 2023

EPS came in at -$0.03 surpassing the estimated -$0.10 by +70.00%, while revenue for the quarter reached $36.16M , missing expectations by -0.10%.

Earnings released on 8 Nov 2022

EPS came in at -$0.01 surpassing the estimated -$0.15 by +93.33%, while revenue for the quarter reached $36.96M , beating expectations by +2.09%.

Earnings released on 3 Aug 2022

EPS came in at -$0.06 surpassing the estimated -$0.15 by +60.00%, while revenue for the quarter reached $34.45M , beating expectations by +1.87%.

Earnings released on 4 May 2022

EPS came in at -$0.20 falling short of the estimated -$0.17 by -17.65%, while revenue for the quarter reached $31.01M , beating expectations by +2.22%.

Earnings released on 22 Feb 2022

EPS came in at -$0.08 surpassing the estimated -$0.13 by +38.46%, while revenue for the quarter reached $31.54M , missing expectations by -0.80%.

Earnings released on 3 Nov 2021

EPS came in at -$0.09 surpassing the estimated -$0.12 by +25.00%, while revenue for the quarter reached $31.20M , missing expectations by -9.95%.

Earnings released on 4 Aug 2021

EPS came in at -$0.09 surpassing the estimated -$0.12 by +25.00%, while revenue for the quarter reached $33.58M , meeting expectations.

Earnings released on 5 May 2021

EPS came in at -$0.08 surpassing the estimated -$0.17 by +52.94%, while revenue for the quarter reached $31.04M , missing expectations by -25.93%.

Earnings released on 22 Feb 2021

EPS came in at -$0.08 surpassing the estimated -$0.11 by +27.27%, while revenue for the quarter reached $32.50M , missing expectations by -25.00%.

Earnings released on 29 Oct 2020

EPS came in at $0.04 surpassing the estimated -$0.13 by +130.77%, while revenue for the quarter reached $33.43M , missing expectations by -88.03%.

AXGN Stock Performance

Access detailed AXGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run